Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Csl
Thumbnail
February 28, 2022

A big year for sickle cell

Novel approaches including gene editing are creeping towards approval.

Thumbnail
December 15, 2021

Biopharma’s buyout year ends with a bang

A recent buying spree swells 2021's meagre M&A tally, but the Pfizer-Arena deal could crystallise antitrust concerns.

Article image
Vantage logo
December 14, 2021

CSL pays $11.7bn for new blood

The biggest biopharma deal of the year is also the biggest the Australian group has ever done.

Article image
Vantage logo
December 09, 2021

Hope for Uniqure, at the third time of asking

Article image
Vantage logo
November 02, 2021

Centessa claims a place in the antitrypsin deficiency pipeline

But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.

Article image
Vantage logo
September 09, 2021

Centessa takes a step towards a new haemophila mechanism

Article image
Vantage logo
July 01, 2021

Pharming turns to gene therapy for next-gen HAE therapy

Article image
Vantage logo
March 29, 2021

Uniqure tries to restore gene therapy calm

Article image
Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

As Biontech and Pfizer’s Covid-19 vaccine gets a positive US vote, delays for Sanofi, Glaxo and CSL show that top-speed drug development is the exception.

Article image
Vantage logo
September 11, 2020

A rare yet early-stage win for Galapagos and Gilead in scleroderma

Article image
Vantage logo
July 14, 2020

Roche reaches deep once again

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.